Potential of combination therapy in EGFR mutated lung cancer

Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan Correspondence to: Makoto Maemondo, MD, PhD. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, Japan. Email: maemondo-ma693@aioros.ocn.ne.jp. Provenance and Peer Review: This article is commissioned and reviewed by the Section Editor Dr. Song Xu (Department of lung cancer surgery, Tianjin Medical University General Hospital; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin, China). Response to: Horinouchi H. To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer. Ann Transl Med 2020. [Epub ahead of print]. doi: 10.21037/atm.2020.01.66 Adderley H, Ackermann CJ, Califano R. Erlotinib plus bevacizumab for EGFR-mutant advanced nonsquamous non-small-cell lung cancer patients: ready for firstline? Ann Transl Med 2019;7:S346.